The potential utility of melatonin in the treatment of childhood cancer
| Autor: | Yu-Hua Chao, Shih-Chi Su, Chia-Ming Yeh, Russel J. Reiter, Shun-Fa Yang, Kang Hsi Wu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Treatment response medicine.medical_specialty Physiology Clinical Biochemistry Childhood cancer Antineoplastic Agents Antioxidants Melatonin 03 medical and health sciences Health problems 0302 clinical medicine Neoplasms Internal medicine medicine Humans Child Cause of death business.industry Disease progression Cancer Cell Biology medicine.disease 030104 developmental biology Anticancer treatment 030220 oncology & carcinogenesis Disease Progression business medicine.drug |
| Zdroj: | Journal of Cellular Physiology. 234:19158-19166 |
| ISSN: | 1097-4652 0021-9541 |
| DOI: | 10.1002/jcp.28566 |
| Popis: | Childhood cancer management has improved considerably, with the overall objective of preventing early-life cancers completely. However, cancer remains a major cause of death in children, with the survivors developing anticancer treatment-specific health problems. Therefore, the anticancer treatment needs further improvement. Melatonin is a effective antioxidant and circadian pacemaker. Through multiple mechanisms, melatonin has significant positive effects on multitude adult cancers by increasing survival and treatment response rates, and slowing disease progression. In addition, melatonin appears to be safe for children. As an appealing therapeutic agent, we herein address several key concerns regarding melatonin's potential for treating children with cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text